Hundreds of Israelis who suffered burn wounds on Oct 7 have been treated with pineapple stem based NexoBrid gel from Israel’s MediWound (see here previously). It contains the enzyme bromelain which breaks down dead tissue in 4 hours, while preserving … Continue reading →

The US Biomedical Advanced Research and Development Authority (BARDA) has awarded $10 million to Israel’s MediWound (see here previously). Part of the funding will be used to extend its NexoBrid license to pediatric burns – 30% of the total burn … Continue reading →

Israel’s Mediwound has received FDA approval for its NexoBrid pineapple plant-based burn treatment (see here previously) to be sold in the US to treat thermal burns. The US already has emergency stockpiles. NexoBrid is now approved for use in 44 … Continue reading →

Israel’s MediWound (see here previously) successfully completed Phase 3 clinical trials of its NexoBrid treatment on children with severe thermal burns. The study evaluated 145 pediatric patients, from newborn to eighteen years of age, across 36 burn centers worldwide. https://www.timesofisrael.com/israels-mediwound-says-key-trial-shows-pineapple-gel-effective-for-kids-burns/

Israel’s Mediwound (reported here previously) has delivered its first batch of its Nexobrid treatment for burns to BARDA (the Biomedical Advanced Research and Development Authority) for the US Department of Health’s emergency response preparedness. http://ir.mediwound.com/news-releases/news-release-details/mediwound-and-vericel-announce-acceptance-first-delivery

As per its 2015 contract with Israel’s MediWound (see here), the U.S. Department of Health (HSS), is stockpiling $16.5 million worth of MediWound’s NexoBrid burns treatment. HSS has options on another $50 million of NexoBrid. http://www.globenewswire.com/fr/news-release/2020/01/06/1966319/0/en/BARDA-Initiates-the-Procurement-of-NexoBrid-for-Emergency-Response.html

I reported previously (see here) on the innovative NexoBrid treatment for severe burns from Israel’s MediWound. MediWound has just announced positive top line results of its pivotal U.S. Phase 3 clinical study. Dead skin was completely removed from 93% of … Continue reading →

The US Biomedical Advanced Research and Development Authority (BARDA) has invested $43 million in Israel’s MediWound to develop its NexoBrid product for the treatment of mustard gas injuries. In 2015 BARDA invested $112 million to help MediWound develop NexoBrid for … Continue reading →